Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Extended Sale! Save on premium data with Claim 60% OFF
Close

Moderna Inc (MRNA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
73.48 -0.25    -0.34%
17:00:45 - Real-time Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Italy
ISIN:  US60770K1079 
  • Volume: 100
  • Bid/Ask: 72.69 / 73.32
  • Day's Range: 73.48 - 73.48
Moderna 73.48 -0.25 -0.34%

MRNA Income Statement

 
Featured here, the Income Statement (earnings report) for Moderna Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2023
30/09
 2023
30/06
 2023
31/03
 2022
31/12
Total Revenue 1831 344 1862 5084
Revenue 1757 293 1828 5084
Other Revenue, Total 74 51 34 -
Cost of Revenue, Total 3401 1879 1923 3129
Gross Profit -1570 -1535 -61 1955
Total Operating Expenses 3843 2211 2228 3504
Selling/General/Admin. Expenses, Total 442 332 305 375
Research & Development 1160 1148 1131 1211
Depreciation / Amortization 419 - 78 -
Interest Expense (Income) - Net Operating -10 -13 -9 -10
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -1150 -1135 -1122 -1201
Operating Income -2012 -1867 -366 1580
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets -37 22 -35 -2
Other, Net -17 -140 -26 -73
Net Income Before Taxes -1958 -1749 -305 1655
Provision for Income Taxes 1672 -369 -384 190
Net Income After Taxes -3630 -1380 79 1465
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items -3630 -1380 79 1465
Total Extraordinary Items - - - -
Net Income -3630 -1380 79 1465
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items -3630 -1380 79 1465
Dilution Adjustment 0.93 -0.78 2.05 -8.18
Diluted Net Income -3630.93 -1379.22 76.95 1473.18
Diluted Weighted Average Shares 381 381 405 405
Diluted EPS Excluding Extraordinary Items -9.53 -3.62 0.19 3.64
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -3.15 -2.91 -0.417 2.56
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MRNA Comments

Write your thoughts about Moderna Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email